USP7抑制剂破坏EBNA1的稳定,并抑制爱斯坦-巴尔病毒瘤发生
Christopher Chen1, Kush Addepalli2, Samantha S Soldan1
1The Wistar Institute, Philadelphia, Pennsylvania, USA.
Journal of medical virology
|January 17, 2025
概括
准USP7降低了爱斯坦-巴尔病毒核抗原-1 (EBNA1) 蛋白质水平,抑制病毒插曲复制和EBV+细胞增殖. 美国P7抑制剂在治疗EBV相关癌症方面表现有前途.
科学领域:
- 病毒学 病毒学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 是一种常见的人类疹病毒,与伯基特淋巴瘤和胃癌等癌症有关.
- 病毒蛋白EBV核抗原-1 (EBNA1) 维护了EBV基因组作为感染细胞中的病组.
- EBNA1的稳定性对EBV的持久性至关重要,并由全素特异性蛋白酶7 (USP7) 调节.
研究的目的:
- 调查USP7向对EBNA1稳定性和功能的影响.
- 评估USP7抑制剂在与EBV相关的恶性瘤中的治疗潜力.
主要方法:
- 用USP7抑制剂和siRNA治疗EBV+细胞.
- 蛋白质组分析以确定EBNA1互动组变化.
- 检测EBNA1的DNA结合和发症复制号码.
- 转录组分析以评估路径的改变.
- 细胞增殖试验和老鼠异种移植模型.
主要成果:
- 通过USP7抑制,EBNA1蛋白水平通过蛋白酶体降解而降低.
- USP7 抑制剂 GNE6776 破坏了 EBNA1-USP7 相互作用和 EBNA1 与 EBV oriP DNA 的结合.
- 病毒情节复制数和EBV+细胞增殖减少.
- 抑制USP7影响了染色体分离和细胞分裂途径.
- GNE6776减缓了EBV+胃癌和淋巴癌异种移植的瘤生长.
结论:
- USP7是EBNA1稳定性和功能的关键调节者.
- USP7 抑制剂有效地降低了EBV 插曲维持和病毒性瘤发生.
- 针对USP7代表了EBV相关癌症的潜在治疗策略.
更多相关视频
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.1K
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
9.1K
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cross-reactivity
30.9K
Overview
30.9K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
